FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Upgrades View On Shares Of Louisiana-pacific Corp. To Hold From Sell

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raised our target price by $18 to $73 using a normalized equity risk premium and a forward P/E of 29.2x compared to the 3-year historical average of 30.4x on operating earnings. We lower our 2026 EPS estimate by $0.32 to $2.50 and our 2027 estimate by $0.67 to $4.00, just below consensus estimates. Our revenue projections are $2.66B in 2026 and $2.94B in 2027, respectively. LPX saw minimal impact from crude oil price volatility experienced in Q1 2026. This reflects both the near-term agility of the company's supply chain and operations teams as well as the longer-term algorithmic structure of many of its strategic supply contracts. We expect to see modest increases in freight rates, which is not surprising given how quickly diesel prices respond to crude oil supply disruptions. Overall, management stated inflationary impacts were minimal in Q1 2026. LPX secured two new builder partnerships with some of the largest U.S. homebuilders in 2026, and we see more deals ahead.

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL